产品
编 号：F715511
分子式：C13H19N3O7
分子量：329.31
分子式：C13H19N3O7
分子量：329.31
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
350
In-stock
10mg
560
In-stock
25mg
720
In-stock
50mg
1000
In-stock
100mg
1560
In-stock
200mg
2600
In-stock
500mg
6360
In-stock
结构图
CAS No: 2492423-29-5
产品详情
生物活性：
Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza.
体内研究：
Molnupiravir (50-500 mg/kg；口服；每 12 小时一次，持续 3 天) 具有强大的抗病毒作用，能够预防 SARS-CoV 复制和疾病。Molnupiravir (7 mg/kg；口服 每天两次，持续 3.5 天) 显著减少病毒载量和发热持续时间。Animal Model:C57BL/6 mice (intranasal infection with SARS-CoV)
Dosage:50, 150, 500 mg/kg
Administration:Oral; every 12 hours for 3 days
Result:Body weight loss is significantly diminished or prevented.
Animal Model:Ca/09-infected female ferrets
Dosage:7 mg/kg
Administration:Oral; twice daily for 3.5 days
Result:Shed virus load and duration of fever were significantly reduced.
Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza.
体内研究：
Molnupiravir (50-500 mg/kg；口服；每 12 小时一次，持续 3 天) 具有强大的抗病毒作用，能够预防 SARS-CoV 复制和疾病。Molnupiravir (7 mg/kg；口服 每天两次，持续 3.5 天) 显著减少病毒载量和发热持续时间。Animal Model:C57BL/6 mice (intranasal infection with SARS-CoV)
Dosage:50, 150, 500 mg/kg
Administration:Oral; every 12 hours for 3 days
Result:Body weight loss is significantly diminished or prevented.
Animal Model:Ca/09-infected female ferrets
Dosage:7 mg/kg
Administration:Oral; twice daily for 3.5 days
Result:Shed virus load and duration of fever were significantly reduced.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备